,This exam preparation document serves as an authoritative and comprehensive resource for students enrolled in
WGU D116 Advanced Pharmacology. It provides a systematic review of core pharmacological concepts, including
pharmacokinetics and pharmacodynamics, and systematically covers drug classes affecting the autonomic nervous
system, cardiovascular, renal, endocrine, central nervous, respiratory, gastrointestinal, and antimicrobial systems.
Each chapter is reinforced with a robust set of practice questions that mirror the format and difficulty of the actual
final exam, complete with verified answers and in-depth rationales that explain both correct and incorrect options.
The content is meticulously updated to align with the 2026-2027 academic year, ensuring relevance and accuracy.
This document not only aids in content mastery but also enhances critical thinking and clinical application skills
essential for advanced practice. By integrating theoretical knowledge with practical scenarios, it prepares students
to excel in the objective assessment and pre-assessment, ultimately fostering safe and effective pharmacological
prescribing.
Keywords:
Advanced Pharmacology, WGU D116, Pharmacokinetics, Pharmacodynamics, Autonomic Nervous System,
Cardiovascular Pharmacology, Renal Pharmacology, Practice Questions, Test Bank, Exam Prep
Answer Format:
Each practice question is followed by the correct answer and a detailed rationale explaining why the answer is
correct and why the distractors are incorrect. Rationales include relevant pharmacokinetic and pharmacodynamic
principles, clinical application, and evidence-based guidelines to reinforce learning and critical thinking.
Compliance Checklist:
Aligned with WGU D116 course objectives and competencies
Based on the latest 2026-2027 evidence-based practice guidelines
All answers verified by subject matter experts
Includes detailed rationales for every question
Covers all major topics in advanced pharmacology
Suitable for both pre-assessment and final exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 ADME, drug receptors, dose-response, 10%
Pharmacodynamics therapeutic index
Autonomic Nervous System 41-100 Cholinergic agonists/antagonists, adrenergic 15%
Drugs agonists/antagonists
Cardiovascular Pharmacology 101-180 Antihypertensives, antiarrhythmics, heart 20%
failure drugs, lipid-lowering agents
Renal Pharmacology 181-220 Diuretics, electrolyte management, acid-base 10%
disorders
Endocrine Pharmacology 221-280 Insulin, oral antidiabetics, thyroid, adrenal, 15%
sex hormones
Central Nervous System 281-340 Anxiolytics, antidepressants, antipsychotics, 15%
Pharmacology anticonvulsants, sedatives
Respiratory and Gastrointestinal 341-380 Bronchodilators, corticosteroids, 10%
Pharmacology antihistamines, antiemetics, antacids
Antimicrobial and 381-440 Antibiotics, antivirals, antifungals, 15%
Chemotherapy antiparasitics, antineoplastics
Pain Management and 441-480 Opioids, NSAIDs, local anesthetics, general 10%
Anesthesia anesthetics
Page 2
,Special Populations and Drug 481-525 Pediatric, geriatric, pregnancy, drug 10%
Interactions interactions, adverse effects
Page 3
, Q1. In a phase I clinical trial, a novel drug exhibits a volume of distribution of 42 L
and a clearance of 3.5 L/h. If the target steady-state average concentration is 2 mg/L,
which oral dosing regimen (given every 12 hours) most closely achieves this target,
assuming complete oral bioavailability?
A. 84 mg every 12 hours
B. 42 mg every 12 hours
C. 168 mg every 12 hours
D. 21 mg every 12 hours
Correct Answer: A. 84 mg every 12 hours
Rationale: The maintenance dose rate equals clearance times target concentration (3.5
L/h × 2 mg/L = 7 mg/h). Over 12 hours, this requires 84 mg per dose. Thus, 84 mg every
12 hours is correct.
Why Wrong:
B - 42 mg every 12 hours gives only 3.5 mg/h, half the required rate.
C - 168 mg every 12 hours doubles the required rate, leading to twice the target
concentration.
D - 21 mg every 12 hours provides only 1.75 mg/h, a quarter of the needed rate.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 4:
Pharmacokinetics.
Q2. A drug acts as a partial agonist at beta-1 adrenergic receptors. Which statement
best describes its effect on cardiac output when the concentration is high enough to
saturate all receptors, compared to a full agonist at the same receptor?
A. It produces a lower maximum cardiac output than a full agonist.
B. It produces the same maximum cardiac output as a full agonist.
C. It produces a higher maximum cardiac output than a full agonist.
D. It produces no effect on cardiac output regardless of concentration.
Correct Answer: A. It produces a lower maximum cardiac output than a full agonist.
Rationale: A partial agonist has lower intrinsic efficacy than a full agonist; even at full
receptor occupancy, it produces a submaximal response. Therefore, its ceiling effect on
cardiac output is lower.
Why Wrong:
B - A partial agonist cannot achieve the same maximal effect as a full agonist due to
lower intrinsic efficacy.
C - Partial agonists do not produce higher maximal responses than full agonists.
D - A partial agonist does produce some effect, just not maximal.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 3:
Pharmacodynamics.
Page 4
WGU D116 Advanced Pharmacology. It provides a systematic review of core pharmacological concepts, including
pharmacokinetics and pharmacodynamics, and systematically covers drug classes affecting the autonomic nervous
system, cardiovascular, renal, endocrine, central nervous, respiratory, gastrointestinal, and antimicrobial systems.
Each chapter is reinforced with a robust set of practice questions that mirror the format and difficulty of the actual
final exam, complete with verified answers and in-depth rationales that explain both correct and incorrect options.
The content is meticulously updated to align with the 2026-2027 academic year, ensuring relevance and accuracy.
This document not only aids in content mastery but also enhances critical thinking and clinical application skills
essential for advanced practice. By integrating theoretical knowledge with practical scenarios, it prepares students
to excel in the objective assessment and pre-assessment, ultimately fostering safe and effective pharmacological
prescribing.
Keywords:
Advanced Pharmacology, WGU D116, Pharmacokinetics, Pharmacodynamics, Autonomic Nervous System,
Cardiovascular Pharmacology, Renal Pharmacology, Practice Questions, Test Bank, Exam Prep
Answer Format:
Each practice question is followed by the correct answer and a detailed rationale explaining why the answer is
correct and why the distractors are incorrect. Rationales include relevant pharmacokinetic and pharmacodynamic
principles, clinical application, and evidence-based guidelines to reinforce learning and critical thinking.
Compliance Checklist:
Aligned with WGU D116 course objectives and competencies
Based on the latest 2026-2027 evidence-based practice guidelines
All answers verified by subject matter experts
Includes detailed rationales for every question
Covers all major topics in advanced pharmacology
Suitable for both pre-assessment and final exam preparation
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 ADME, drug receptors, dose-response, 10%
Pharmacodynamics therapeutic index
Autonomic Nervous System 41-100 Cholinergic agonists/antagonists, adrenergic 15%
Drugs agonists/antagonists
Cardiovascular Pharmacology 101-180 Antihypertensives, antiarrhythmics, heart 20%
failure drugs, lipid-lowering agents
Renal Pharmacology 181-220 Diuretics, electrolyte management, acid-base 10%
disorders
Endocrine Pharmacology 221-280 Insulin, oral antidiabetics, thyroid, adrenal, 15%
sex hormones
Central Nervous System 281-340 Anxiolytics, antidepressants, antipsychotics, 15%
Pharmacology anticonvulsants, sedatives
Respiratory and Gastrointestinal 341-380 Bronchodilators, corticosteroids, 10%
Pharmacology antihistamines, antiemetics, antacids
Antimicrobial and 381-440 Antibiotics, antivirals, antifungals, 15%
Chemotherapy antiparasitics, antineoplastics
Pain Management and 441-480 Opioids, NSAIDs, local anesthetics, general 10%
Anesthesia anesthetics
Page 2
,Special Populations and Drug 481-525 Pediatric, geriatric, pregnancy, drug 10%
Interactions interactions, adverse effects
Page 3
, Q1. In a phase I clinical trial, a novel drug exhibits a volume of distribution of 42 L
and a clearance of 3.5 L/h. If the target steady-state average concentration is 2 mg/L,
which oral dosing regimen (given every 12 hours) most closely achieves this target,
assuming complete oral bioavailability?
A. 84 mg every 12 hours
B. 42 mg every 12 hours
C. 168 mg every 12 hours
D. 21 mg every 12 hours
Correct Answer: A. 84 mg every 12 hours
Rationale: The maintenance dose rate equals clearance times target concentration (3.5
L/h × 2 mg/L = 7 mg/h). Over 12 hours, this requires 84 mg per dose. Thus, 84 mg every
12 hours is correct.
Why Wrong:
B - 42 mg every 12 hours gives only 3.5 mg/h, half the required rate.
C - 168 mg every 12 hours doubles the required rate, leading to twice the target
concentration.
D - 21 mg every 12 hours provides only 1.75 mg/h, a quarter of the needed rate.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 4:
Pharmacokinetics.
Q2. A drug acts as a partial agonist at beta-1 adrenergic receptors. Which statement
best describes its effect on cardiac output when the concentration is high enough to
saturate all receptors, compared to a full agonist at the same receptor?
A. It produces a lower maximum cardiac output than a full agonist.
B. It produces the same maximum cardiac output as a full agonist.
C. It produces a higher maximum cardiac output than a full agonist.
D. It produces no effect on cardiac output regardless of concentration.
Correct Answer: A. It produces a lower maximum cardiac output than a full agonist.
Rationale: A partial agonist has lower intrinsic efficacy than a full agonist; even at full
receptor occupancy, it produces a submaximal response. Therefore, its ceiling effect on
cardiac output is lower.
Why Wrong:
B - A partial agonist cannot achieve the same maximal effect as a full agonist due to
lower intrinsic efficacy.
C - Partial agonists do not produce higher maximal responses than full agonists.
D - A partial agonist does produce some effect, just not maximal.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th ed., Ch. 3:
Pharmacodynamics.
Page 4
